文献速递冠心病

复杂高危 PCI 患者坎格瑞洛用药与临床结局的真实世界研究

Cangrelor Dosing, Administration, and Clinical Outcomes for Patients Undergoing Complex and High‐Risk Percutaneous Coronary Interventions
RSS 订阅 · Catheterization and Cardiovascular Interventions · 2026-10-13

一项美国回顾性医生小组病历回顾研究纳入 200 例接受坎格瑞洛治疗的复杂高危 PCI 患者,评估给药方式及 48 小时内临床结局。87.5% 的患者接受了符合推荐方案的负荷剂量与维持输注,但 64.9% 的患者输注时长偏离至少 2 小时或 PCI 时长的推荐。偏离推荐时长的患者 MACE 发生比例更高,提示需关注给药依从性对结局的影响。

要点

  • 坎格瑞洛用于复杂高危 PCI 时,输注时长偏离推荐方案的比例较高。
  • 偏离推荐输注时长的患者 MACE 发生比例高于依从推荐时长的患者。
  • 临床应严格遵循坎格瑞洛负荷剂量与维持输注时长的推荐方案。

核心结论

  • 复杂高危 PCI 患者中坎格瑞洛输注时长存在显著差异,偏离推荐时长者 MACE 发生比例更高。

研究设计与样本

  • 美国回顾性医生小组病历回顾研究,纳入 2020 年 1 月 1 日至 2025 年 6 月 26 日期间 18 岁及以上在复杂高危 PCI 中接受坎格瑞洛治疗的患者 200 例。
  • 首次坎格瑞洛给药日期设为索引日期,基线特征采集自索引前 6 个月,临床结局观察 48 小时内。

主要发现

  • 200 例患者中男性占 85.5%,平均年龄 63 岁,平均 BMI 30.2 kg/m²。
  • 87.5% 的患者接受了坎格瑞洛负荷剂量 30.0 µg/kg 及维持输注 4.0 µg/kg/min。
  • 总体 30 例患者发生 MACE;偏离推荐时长者 MACE 比例为 16.1%(95% CI 3.5%–23.1%),依从者为 10.6%(95% CI 9.1%–25.5%)。

关键数值与推荐

  • 坎格瑞洛推荐负荷剂量为 30.0 µg/kg,维持输注剂量为 4.0 µg/kg/min。
  • 推荐输注时长为至少 2 小时或持续至 PCI 结束。

临床怎么用

  • 复杂高危 PCI 使用坎格瑞洛时,应严格执行负荷剂量与维持输注方案,避免输注时长不足。
  • 对输注时长偏离推荐的患者应加强监测,警惕急性血栓事件风险。

局限性

  • 研究为回顾性病历回顾设计,可能存在信息偏倚与混杂因素。
  • 输注时长分析仅纳入 134 例患者,未说明部分患者数据缺失的原因。
  • MACE 组间比较未报告统计学检验结果,不能确定差异是否具有统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high-risk PCI (CHIP). Aims We evaluated the real-world administration of cangrelor and related health outcomes for CHIP patients. Methods A US retrospective physician panel medical chart review (1/1/2020 to 6/26/2025) included patients 18+ years old who received cangrelor (1st dose = index date) during CHIP. We summarized patients' characteristics in the 6 months pre-index (baseline), cangrelor dosing and administration (IV bolus and/or infusion), and clinical outcomes within 48 h. We described MACE occurrence by dosing adherence. Results Patients (n = 200) were mostly male (85.5%), had a mean age of 63 years, and had a BMI of 30.2 kg/m2. Most (87.5%) received a cangrelor bolus (30.0 µg/kg) and maintenance infusion (4.0 µg/kg/mins), aligned with intended use recommendations. Of patients analyzed for infusion duration (n = 134), 64.9% deviated from the recommendation of at least 2 h or PCI length. Forty (29.9%) received cangrelor for less than the recommended duration. Overall, 30 (15%) patients experienced MACE, with a higher proportion of MACE seen in those who deviated from the recommended duration (16.1% [95% CI: 3.5%–23.1%] vs. 10.6% [95% CI: 9.1%–25.5%]). Conclusions Our study provides real-world insight into cangrelor use and clinical outcomes in CHIP patients, highlighting notable variability in infusion duration and differences in MACE occurrence by dosing adherence. Further comparative effectiveness studies are warranted to examine the potential impact of deviation from intended dose/duration on clinical outcomes in CHIP.

来源:Catheterization and Cardiovascular Interventions,查看原文。版权归原作者所有。

引用

  1. Catheterization and Cardiovascular Interventions:Cangrelor Dosing, Administration, and Clinical Outcomes for Patients Undergoing Complex and High‐Risk Percutaneous Coronary Interventions

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。